Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude To Announce RHYTHM Data As ACC Crowd Buzzes About SCD-HeFT

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical will present results from three pivotal cardiac rhythm management trials during the Annual Scientific Sessions of the American College of Cardiology in New Orleans, March 6-10

You may also be interested in...



American College Of Cardiology 2004 Scientific Sessions In Brief

Expanded Cypher use: Sirolimus-eluting stents are effective in treating lesions in relatively narrow vessels, according to eight-month data from the 257-patient SES-SMART trial comparing Johnson & Johnson/Cordis' Cypherwith the firm's bare-metal Bx Velocity. Binary restenosis was 9.8% and 53.1% for the Cypher and control groups, respectively; major cardiac event rates were 9.3% for Cypher and 31.3% for control. Mean vessel diameter was 2.2 mm; mean pre-procedure lumen diameter was 0.72 mm. Cypher currently is approved for vessels 2.5-3.5 mm in diameter...

American College Of Cardiology 2004 Scientific Sessions In Brief

Expanded Cypher use: Sirolimus-eluting stents are effective in treating lesions in relatively narrow vessels, according to eight-month data from the 257-patient SES-SMART trial comparing Johnson & Johnson/Cordis' Cypherwith the firm's bare-metal Bx Velocity. Binary restenosis was 9.8% and 53.1% for the Cypher and control groups, respectively; major cardiac event rates were 9.3% for Cypher and 31.3% for control. Mean vessel diameter was 2.2 mm; mean pre-procedure lumen diameter was 0.72 mm. Cypher currently is approved for vessels 2.5-3.5 mm in diameter...

St. Jude Epic HF

Cardiac resynchronization therapy defibrillator (CRT-D) likely will not require FDA advisory panel review, the firm says. St. Jude expects a planned PMA submission this month to lead to approval in time for the NASPE/Heart Rhythm Society meeting in San Francisco May 19-22. Data from the pivotal RHYTHM trial will be presented at the American College of Cardiology meeting March 7-10 in New Orleans (1"The Gray Sheet" Dec. 1, 2003, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel